fashion -WSS

fashion

author：focus 2025-10-01 23:00:21 - browse：822

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Ebola vaccine can save some who are already sick, per new study

hotspot

focus

WSS

4 dead, 2 in stable condition in Philadelphia shooting: Police

10 states plan to sue EPA over standards for residential wood

Long Covid research funding gets a major boost from NIH

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

Artificial intelligence use in health care faces greater scrutiny in 2024

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

hotspot

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Supreme Court strikes down use of affirmative action

Congress might make insulin pumps more accessible to the blind

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

Medical leaders decry Supreme Court decision on affirmative action

Some in Scotland's Orkney Islands want to return to Norway after 550 years

explore

NASA releases new images of 'fingerprint

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

Congress might make insulin pumps more accessible to the blind

A timeline of the missing Titanic tourist submersible

Why don't Americans have at

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

hotspot

focus

Wikipedia

knowledge